Public health trying to identify owner in Stratford dog biting incident - CTV News

15 hours agoShannen HeadleyWest MidlandsCCLGLiberty York died aged 19, a year after she first experienced symptoms of an angiosarcoma Liberty York was 19 when she died from a rare form of cancer, two days after her birthday. A year after her death, her mother Hannah York has talked about her strength and the parts of her daughter that existed outside of her illness. "The first thing that comes to mind when I think about Liberty is how kind she was and thoughtful," she said. To Hannah, she was still the same determined teenager throughout the final year of her life, before she died from an angiosarcoma, a rare form of soft tissue sarcoma, a type of cancer which starts in areas of the body such as muscle and fat. The first signs appeared in May 2024 when Liberty, from Stratford-upon-Avon, Warwickshire, began feeling unusually tired and nauseous. A year earlier she had been diagnosed with Addison's disease, a rare autoimmune condition, so at first the family thought it was possible the two could be linked. Liberty was referred to see a specialist but while the family waited for answers, she developed swelling and pain in her left breast.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.